He aha ka Inebilizumab: Nā hoʻohana, ka nui, nā hopena ʻaoʻao a me nā mea hou aku

He lāʻau lapaʻau kūikawā ʻo Inebilizumab i hoʻolālā ʻia e mālama i ka maʻi spectrum neuromyelitis optica (NMOSD), kahi maʻi autoimmune laha ʻole e hoʻouka ana i nā aʻalolo optic a me ke kuamoʻo. Hana kēia lāʻau lapaʻau ma ka ʻimi ʻana i nā cell immune kikoʻī i kapa ʻia ʻo B cells e kōkua i ka mumū a me ka pōʻino i ʻike ʻia ma NMOSD.

Inā ua ʻike ʻia ʻoe a i ʻole kekahi āu e mālama nei me NMOSD, e manaʻo paha ʻoe e lanakila ʻia e ka paʻakikī o kēia maʻi. ʻO ka hoʻomaopopo ʻana i kāu mau koho lapaʻau, me ka inebilizumab, hiki ke kōkua iā ʻoe e manaʻoʻiʻo e pili ana i ka mālama ʻana i kēia maʻi paʻakikī.

He aha ka Inebilizumab?

ʻO Inebilizumab kahi lāʻau lapaʻau monoclonal antibody e kōkua ana i ka mālama ʻana i ka maʻi spectrum neuromyelitis optica ma ka ʻimi ʻana i kāu ʻōnaehana pale. Ua hoʻolālā kūikawā ʻia e hoʻopaʻa i nā cell B CD19-positive, ʻo ia nā cell immune e pāʻani i kahi hana nui i ka hoʻouka autoimmune e hōʻike ana iā NMOSD.

No ka papa o nā lāʻau lapaʻau i kapa ʻia ʻo immunosuppressants kēia lāʻau lapaʻau, ʻo ia hoʻi e hōʻemi ana i ka hana o kāu ʻōnaehana pale. ʻOiai e like paha kēia me ka hopohopo, he mea kōkua maoli ia i ka NMOSD no ka mea ke hoʻouka hewa nei kāu ʻōnaehana pale i ka ʻiʻo olakino i loko o kāu ʻōnaehana nerve.

Hāʻawi ʻia ka lāʻau lapaʻau ma ke ʻano he infusion intravenous, ʻo ia hoʻi ua hāʻawi pololei ʻia i loko o kou kahe koko ma o ka vein. Hoʻopaʻa kēia ʻano i ka lāʻau lapaʻau i nā wahi kūpono i loko o kou kino kahi e pono ai.

No ke aha e hoʻohana ʻia ai ka Inebilizumab?

Hoʻohana nui ʻia ʻo Inebilizumab e mālama i nā pākeke me ka maʻi spectrum neuromyelitis optica (NMOSD). He maʻi autoimmune laha ʻole ʻo NMOSD kahi e hoʻouka ai kāu ʻōnaehana pale i ka uhi pale a puni kou mau aʻalolo optic a me ke kuamoʻo, e hoʻoulu ai i ka mumū a me ka pōʻino.

Ua ʻae ʻia kēia lāʻau lapaʻau no nā kānaka i loaʻa nā antibodies aquaporin-4 (AQP4), i loaʻa ma kahi o 70-80% o nā kānaka me NMOSD. He mau hōʻailona molekala kēia mau antibodies e kōkua ana i nā kauka e hōʻoia i ka maʻi a e wānana i ke ʻano o ka holomua ʻana o ka maʻi.

ʻO ka pahuhopu nui o ka mālama ʻana me ka inebilizumab, ʻo ia ka pale ʻana i nā relapses a i ʻole nā hoʻouka ʻana o NMOSD. I ka wā o ka relapse, hiki iā ʻoe ke ʻike i nā hōʻailona e like me ka nalowale o ka ʻike, ka nāwaliwali, ka ʻeha, a i ʻole nā pilikia me ka hana ʻana o ka ʻōpū a me ka ʻōpū. Ma ka hōʻemi ʻana i ke alapine o kēia mau hoʻouka ʻana, kōkua ka inebilizumab i ka mālama ʻana i kāu hana neurological a me ka maikaʻi o ke ola.

Pehea e Hana ai ʻo Inebilizumab?

Hana ʻo Inebilizumab ma ka ʻimi ʻana a me ka hoʻopau ʻana i nā pūnaewele B-positive CD19 i loko o kāu ʻōnaehana pale. ʻO nā pūnaewele B he mau keʻokeʻo keʻokeʻo e kōkua maʻamau i ka hakakā ʻana i nā maʻi, akā i ka NMOSD, kōkua lākou i ka hoʻouka autoimmune i kāu ʻōnaehana nerve.

E noʻonoʻo i kāu ʻōnaehana pale e like me kahi hui palekana nui e hoʻouka hewa ana i kou kino ponoʻī. Hana ʻo Inebilizumab e like me ka luna e wehe pono i nā kiaʻi palekana (nā pūnaewele B) e hana nei i ka pilikia nui, me ka waiho ʻana i nā ʻāpana ʻē aʻe o kāu ʻōnaehana pale i kahi kūlana maikaʻi.

Ua manaʻo ʻia he lāʻau lapaʻau immunosuppressive ikaika. Ua ʻoi aku ka pahuhopu ma mua o kekahi mau immunosuppressants kahiko, ʻo ia hoʻi hiki ke maikaʻi me ka hiki ke hana i nā hopena ʻaoʻao liʻiliʻi ma mua o nā lāʻau lapaʻau e hoʻopau ana i ka pale.

Noho ka lāʻau lapaʻau i loko o kāu ʻōnaehana no kekahi mau mahina ma hope o kēlā me kēia infusion, e hāʻawi ana i ka pale mau ʻana i nā relapses NMOSD. Pono ka hapa nui o nā kānaka i nā infusions i kēlā me kēia ʻeono mahina e mālama i kēia hopena pale.

Pehea e Lawe ai au i ka Inebilizumab?

Hāʻawi ʻia ʻo Inebilizumab ma ke ʻano he infusion intravenous ma kahi keʻena lapaʻau, maʻamau he haukapila a i ʻole ke kikowaena infusion. ʻAʻole hiki iā ʻoe ke lawe i kēia lāʻau lapaʻau ma ka home, no ka mea, pono ia i ka nānā pono ʻana e nā poʻe loea mālama ola i ka wā e lawelawe ai.

Ma mua o kēlā me kēia hoʻokomo ʻana, e loaʻa ana iā ʻoe nā lāʻau lapaʻau ma mua e kōkua ai i ka pale ʻana i nā hopena o ka hoʻokomo ʻana. Hiki i kēia mau mea ke komo i nā antihistamines e like me ka diphenhydramine (Benadryl) a me nā corticosteroids e like me ka methylprednisolone. E hāʻawi kāu hui mālama ola iā ʻoe i kēia mau lāʻau lapaʻau ma kahi o 30-60 mau minuke ma mua o kāu hoʻokomo ʻana i ka inebilizumab.

ʻO ka hoʻokomo ʻana iho ma kahi o 90 mau minuke no ka mahele mua a ma kahi o 60 mau minuke no nā mahele ma hope. E noho ʻoluʻolu ʻoe i kēia manawa, a e nānā nā kahu hānai i kāu mau hōʻailona ola a nānā i nā hōʻailona o ka hopena.

ʻAʻole pono ʻoe e hahai i nā kapu meaʻai kūikawā ma mua a ma hope paha o kāu hoʻokomo ʻana. Eia naʻe, he manaʻo maikaʻi e ʻai i ka ʻai māmā ma mua o ka hele ʻana i kāu manawa a e noho maikaʻi i ka wai. Manaʻo kekahi poʻe he mea kōkua ke lawe mai i kahi puke, papa, a i ʻole nā hana mālie ʻē aʻe e hala ai ka manawa i ka wā o ka hoʻokomo ʻana.

Pehea ka lōʻihi e lawe ai au i ka Inebilizumab?

He lapaʻau lōʻihi ka Inebilizumab no ka NMOSD, a nui ka poʻe e hoʻomau nei i ka lawe ʻana iā ia no ka pale ʻana i nā relapses. Aia ka lōʻihi o ka lapaʻau i ka maikaʻi o kāu pane ʻana i ka lāʻau lapaʻau a inā paha e loaʻa iā ʻoe kekahi hopena ʻaoʻao koʻikoʻi.

Hoʻomaka ka hapa nui o ka poʻe me ʻelua hoʻokomo mua i hāʻawi ʻia i ʻelua pule kaʻawale, a laila e hahai ʻia e nā hoʻokomo mālama i kēlā me kēia ʻeono mahina. E nānā kāu kauka i kou kūlana i ka makahiki mua e loiloi i ka maikaʻi o ka hana ʻana o ka lāʻau lapaʻau iā ʻoe.

Hiki i kekahi poʻe ke hoʻokaʻawale i kā lākou hoʻokomo ʻana i kahi mamao loa inā e mau ana lākou a paʻa a me ka relapse-free no ka manawa lōʻihi. Eia naʻe, ʻo ka hoʻōki ʻana i ka lāʻau lapaʻau e alakaʻi pinepine i ka hoʻi ʻana o ka hana maʻi, no laila pono ka hapa nui o ka poʻe e hoʻomau i ka lapaʻau no ka wā lōʻihi.

E loiloi mau kāu hui mālama ola i kāu pane ʻana i ka lapaʻau a me nā hopena ʻaoʻao āu e ʻike nei. E kōkua lākou iā ʻoe e kaupaona i nā pōmaikaʻi o ka hoʻomau ʻana i ka lapaʻau e kūʻē i nā pilikia a i ʻole nā pilikia āu e kū ai.

He aha nā hopena ʻaoʻao o ka Inebilizumab?

E like me nā lāʻau lapaʻau a pau, hiki i ka inebilizumab ke hana i nā hopena ʻaoʻao, akā nui ka poʻe e ʻae maikaʻi iā ia. ʻO ka hoʻomaopopo ʻana i ka mea e manaʻo ai hiki ke kōkua iā ʻoe e ʻike i nā hopena maʻamau i nā hōʻailona e pono ai ka nānā koke.

ʻO nā hopena ʻaoʻao maʻamau āu e ʻike ai, ʻo ia:

• Nā maʻi o ka ʻōnaehana mimi (UTIs)
• ʻEha hui a i ʻole arthralgia
• Nā hopena infusion e like me ke kuni, nā anu, a i ʻole ka ʻōpala
• ʻEha hope
• Luhi
• ʻEha poʻo
• ʻĀwili

ʻO nā hopena infusion paha ka mea e hopohopo nui ʻia i ka wā o ka mālama ʻana. Hiki ke hana pinepine kēia i ka wā a i ʻole ma hope koke o ka infusion a hiki ke komo i nā hōʻailona e like me ke kuni, nā anu, ka nausea, ka ʻeha poʻo, a i ʻole ka ʻōpala ʻili. Ua mākaukau kāu hui mālama ola e mālama i kēia mau hopena inā loaʻa.

ʻO nā hopena ʻaoʻao koʻikoʻi akā ʻaʻole maʻamau, hiki ke komo i nā maʻi koʻikoʻi, no ka mea, hoʻopau ka inebilizumab i kāu ʻōnaehana pale. Hiki paha iā ʻoe ke maʻalahi i nā maʻi bacteria, viral, a i ʻole fungal, ʻoi aku hoʻi i ka ʻōnaehana hanu a i ʻole ka ʻōnaehana mimi.

I nā manawa liʻiliʻi loa, hiki i kekahi poʻe ke ʻike i ka hoʻāla hou ʻana o nā maʻi viral dormant e like me ka hepatitis B a i ʻole e hoʻomohala i kahi maʻi lolo koʻikoʻi i kapa ʻia ʻo progressive multifocal leukoencephalopathy (PML). E nānā kāu kauka i kēia mau pilikia ma mua o ka hoʻomaka ʻana i ka mālama ʻana a e nānā pono iā ʻoe i kāu papa hana lapaʻau.

ʻO wai ka mea pono ʻole e lawe i ka Inebilizumab?

ʻAʻole kūpono ka Inebilizumab no nā mea a pau me NMOSD. E loiloi pono kāu kauka i kāu mōʻaukala olakino a me ke kūlana olakino i kēia manawa ma mua o ka ʻōlelo ʻana i kēia lapaʻau.

ʻAʻole pono ʻoe e lawe i ka inebilizumab inā loaʻa iā ʻoe kahi maʻi koʻikoʻi, ʻaʻole i mālama ʻia a hoʻoponopono ʻia. Aia kēia i nā maʻi bacteria e like me ka pneumonia, nā maʻi viral e like me ka hepatitis B, a i ʻole nā maʻi fungal e hiki ke hōʻino me ka hoʻopau ʻana i ka immune.

Pono ka poʻe me ka moʻolelo o ka maʻi hepatitis B i ka noʻonoʻo kūikawā, no ka mea, hiki i ka inebilizumab ke hoʻāla hou i ka maʻi. E hoʻāʻo kāu kauka no ka hepatitis B ma mua o ka hoʻomaka ʻana i ka lāʻau a hiki ke ʻōlelo i nā lāʻau antiviral inā pono.

Inā hāpai ʻoe a i ʻole e hoʻolālā ana e hāpai, ʻaʻole i ʻōlelo ʻia ka inebilizumab. Hiki i ka lāʻau lapaʻau ke hele i ka placenta a hiki ke hoʻopilikia i ka ʻōnaehana pale o kāu pēpē e ulu ana. Pono nā wahine o ka makahiki hānau ke hoʻohana i ka contraception maikaʻi i ka wā o ka lāʻau a no ʻeono mahina ma hope o ka lāʻau hope loa.

ʻAʻole paha he moho maikaʻi ka poʻe me kekahi mau ʻano maʻi maʻi, ʻoi aku ka maʻi koko, no ka inebilizumab. E loiloi kāu kauka i kāu moʻolelo maʻi a me ke kūlana o kēia manawa i ka wā e noʻonoʻo ai i kēia koho lapaʻau.

Inoa Brand Inebilizumab

Hoʻolaha ʻia ʻo Inebilizumab ma lalo o ka inoa brand Uplizna ma ʻAmelika Hui Pū ʻIa. ʻO kēia ka inoa kalepa āu e ʻike ai ma kāu kauoha a me ka ʻeke lāʻau.

ʻO ka inoa generic piha ʻo inebilizumab-cdon, kahi e pili ana ka

ʻO Eculizumab (Soliris) kekahi lāʻau lapaʻau i ʻae ʻia e ka FDA no ka NMOSD e hana ʻokoʻa ma mua o ka inebilizumab. Ma kahi o ka hoʻopaʻa ʻana i nā pūnaewele B, e ālai ana ia i kahi ʻāpana o ka ʻōnaehana complement, ʻo ia kekahi mea o ka ʻōnaehana immune e pili ana i ka NMOSD.

ʻO Satralizumab (Enspryng) kahi koho hou e hoʻopaʻa ana i ka interleukin-6, kahi protein e hoʻolaha i ka mumū. Hiki ke hāʻawi ʻia ma ke ʻano he injection subcutaneous, kahi mea makemake kekahi poʻe ma mua o nā infusions intravenous.

Hiki ke hoʻohana ʻia nā lāʻau immunosuppressive kuʻuna e like me azathioprine, mycophenolate mofetil, a i ʻole corticosteroids, ʻoiai inā ʻaʻole hiki ke kiʻi ʻia nā lāʻau lapaʻau hou a i ʻole kūpono no kou kūlana.

Ua ʻoi aku ka maikaʻi o Inebilizumab ma mua o Rituximab?

He mau lāʻau lapaʻau maikaʻi ʻo Inebilizumab a me rituximab no ka NMOSD, akā he mau ʻokoʻa nui ko lākou e hiki ai ke kūpono kekahi no kou kūlana.

Loaʻa iā Inebilizumab ka pōmaikaʻi o ka ʻae ʻia e ka FDA no ka NMOSD, ʻo ia hoʻi ua hala ia i nā hoʻokolohua lapaʻau koʻikoʻi no kēia maʻi. Ua hōʻike ka ʻikepili hoʻokolohua lapaʻau ua hōʻemi ʻo inebilizumab i ka pilikia o ka NMOSD relapses ma kahi o 73% i hoʻohālikelike ʻia me ka placebo.

ʻO Rituximab, ʻoiai ua hoʻohana nui ʻia no ka NMOSD, ua kauoha ʻia

Nā Nīnau i Nīnau Pinepine ʻia e pili ana iā Inebilizumab

He Palekana ʻo Inebilizumab no ka poʻe me nā maʻi autoimmune ʻē aʻe?

Inā loaʻa iā ʻoe nā maʻi autoimmune ʻē aʻe e like me ka rheumatoid arthritis a i ʻole ka multiple sclerosis, hiki nō paha ʻo inebilizumab i kahi koho, akā pono e loiloi pono. E noʻonoʻo kāu kauka i ke ʻano o ka launa ʻana o inebilizumab me kāu mau maʻi a me nā lāʻau lapaʻau ʻē aʻe.

Hiki i ka loaʻa ʻana o nā maʻi autoimmune he nui ke hana i ka lapaʻau ʻana i kekahi manawa, akā ʻaʻole ia e kāpae ʻakomi iā inebilizumab. E kaupaona kāu hui mālama ola i nā pōmaikaʻi o ka mālama ʻana i kāu NMOSD e kūʻē i nā pilikia e hiki mai ana i kāu mau maʻi ʻē aʻe.

ʻIke kekahi poʻe i ke kōkua ʻana o inebilizumab i nā hōʻailona autoimmune ʻē aʻe, no ka mea, he kuleana ko nā cell B i nā hana autoimmune like ʻole. Eia naʻe, ʻaʻole i hōʻoia ʻia kēia, a ua ʻae ʻia ka lāʻau lapaʻau no NMOSD wale nō.

He aha kaʻu e hana ai inā ua hala au i kahi mahele o Inebilizumab?

Inā ua hala ʻoe i kāu hoʻokomo inebilizumab i hoʻonohonoho ʻia, e hoʻokaʻaʻike i kāu mea mālama ola i ka hiki wawe e hoʻonohonoho hou. ʻAʻole like me nā lāʻau lapaʻau i kēlā me kēia lā, ʻo ka hala ʻana i kahi manawa hoʻokomo ʻaʻole ia e hana i kahi pilikia koke, akā he mea nui e mālama i kāu papa hana lapaʻau.

Hiki i kāu kauka ke ʻōlelo e kiʻi i ka mahele i hala i ka hiki wawe, a i ʻole e hoʻoponopono lākou i kāu papa hana ma muli o ka lōʻihi o ka hala ʻana mai kāu hoʻokomo hope loa. Noho ka lāʻau lapaʻau i loko o kāu ʻōnaehana no kekahi mau mahina, no laila aia ka maʻalahi i ka manawa.

Mai hoʻāʻo e pāpālua i nā mahele a i ʻole e hoʻololi i kāu papa hana me ka ʻole e kūkākūkā me kāu hui mālama ola. E kōkua lākou iā ʻoe e hoʻi i ke ala me kāu hoʻolālā lapaʻau ma ke ala palekana loa.

He aha kaʻu e hana ai inā loaʻa iaʻu nā hopena ʻaoʻao i ka wā o ka hoʻokomo ʻana?

Inā loaʻa iā ʻoe kekahi mau hōʻailona e hopohopo nei i ka wā o kāu hoʻokomo ʻana i ka inebilizumab, e hōʻike koke i kāu kahu hānai a i ʻole ke kauka lapaʻau. Ua lako pono nā kikowaena hoʻokomo e mālama i nā hopena, a ua aʻo ʻia nā limahana e pane koke.

Hiki ke mālama pinepine ʻia nā hopena hoʻokomo maʻamau e like me ke kuni māmā, nā anu, a i ʻole ka ʻūlū ʻana ma ka hoʻolohi ʻana i ka helu hoʻokomo a i ʻole ka hāʻawi ʻana i nā lāʻau lapaʻau mua. Pono paha nā hopena koʻikoʻi e hoʻōki i ka hoʻokomo ʻana no ka manawa a i ʻole mau loa.

E loaʻa i kāu hui mālama ola nā lāʻau lapaʻau pilikia inā pono, me nā antihistamines, corticosteroids, a me epinephrine. Hiki ke mālama ʻia ka hapa nui o nā hopena hoʻokomo a ʻaʻole ia e pale i ka poʻe mai ka hoʻomau ʻana i ka mālama ʻana.

I ka manawa hea e hiki ai iaʻu ke hooki i ka lawe ʻana i ka Inebilizumab?

Pono e hana mau ʻia ka hoʻoholo e hooki i ka inebilizumab ma ke kūkākūkā ʻana me kāu hui mālama ola. Pono ka hapa nui o ka poʻe me NMOSD i ka mālama lōʻihi e pale i nā relapses, a ʻo ka hooki ʻana i ka lāʻau lapaʻau e alakaʻi pinepine i ka hoʻihoʻi ʻana o ka hana maʻi.

Hiki i kāu kauka ke noʻonoʻo e hooki a hoʻololi paha i kāu lapaʻau inā loaʻa iā ʻoe nā hopena ʻaoʻao koʻikoʻi e ʻoi aku ka maikaʻi, inā paʻa kāu maʻi no ka manawa lōʻihi, a i ʻole inā loaʻa nā koho lapaʻau maikaʻi aʻe.

Hiki i kekahi poʻe ke hoʻololi i kahi lāʻau lapaʻau ʻē aʻe ma mua o ka hooki ʻana i ka mālama ʻana. Aia kēia hoʻoholo i kāu pane pilikino i ka mālama ʻana a me ke kūlana olakino holoʻokoʻa.

Hiki iaʻu ke loaʻa nā lāʻau lapaʻau i ka wā e lawe ana i ka Inebilizumab?

Pono ka lāʻau lapaʻau i ka wā e lawe ana i ka inebilizumab i ka noʻonoʻo kūikawā no ka mea e pili ana ka lāʻau lapaʻau i kāu ʻōnaehana pale. ʻAʻole pono ʻoe e loaʻa nā lāʻau lapaʻau ola i ka wā e lawe ana i ka inebilizumab, no ka mea, hiki iā lākou ke hoʻoulu i ka maʻi.

He palekana ka maʻamau o nā lāʻau lapaʻau ʻole e like me ka pana flu a i ʻole nā lāʻau lapaʻau COVID-19, akā ʻaʻole paha lākou e like me ka maikaʻi e like me ka mea i loko o kekahi me kahi ʻōnaehana pale piha. E ʻōlelo ke kauka iā ʻoe i ka manawa maikaʻi loa no nā lāʻau lapaʻau.

He mea maikaʻi ka loaʻa ʻana o nā lāʻau lapaʻau e pono ai ma mua o ka hoʻomaka ʻana i ka inebilizumab inā hiki. E hana kāu hui mālama ola i kahi hoʻolālā lāʻau lapaʻau e mālama iā ʻoe i ka palekana me ka hōʻemi ʻana i nā pilikia mai kāu lapaʻau.